Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07042698

Evaluation of the Performance of Glomerular Filtration Rate Measurement Using CT Urography in Patients With a GFR Below 60 mL/Min/1.73 m²

Glomerular filtration rate (GFR), which is the main biomarker used in clinical practice to assess kidney function, is usually estimated from the serum concentration of endogenous markers such as creatinine and/or cystatin C. GFR estimation equations all share the disadvantage of imperfect accuracy due to non-GFR-related determinants of creatinine and cystatin C. When knowing the exact GFR value is necessary for clinical decision-making, measurement by clearance of an exogenous tracer is required. Various tracers are available, some of which are radioactive tracers (99mTc-DTPA and 51Cr-EDTA), while others are iodinated contrast agents (iohexol, iothalamate). GFR measurement procedures are time-consuming and require significant human resources (4 to 5 hours, or even 24 hours for plasma clearances at very low GFR values).Urinary clearance methods may be inaccurate in cases of inadequate voiding. Plasma clearance results may be inaccurate in cases of increased (overestimation) or decreased (underestimation) extracellular volume, low GFR (unless late sampling is performed), or glomerular hyperfiltration. Measuring tracers requires either warm labs for measuring radioactive markers or labs with HPLC (High Performance Liquid Chromatography) chains for iohexol, which are part of an external quality assurance program. The complexity and/or length of GFR measurement procedures, their cost, and laboratory constraints explain why measured GFR is underused in routine clinical practice. There is a critical need to develop GFR measurement methods that are simpler to implement, reliable across the entire GFR spectrum, and widely available. We have demonstrated that it is possible to measure GFR using 4-phase CT urography performed as part of the care of living kidney donor candidates (healthy individuals with normal GFR). The examination takes 10 minutes, requires no biological sampling, and is not subject to potential inaccuracies due to sodium overload or poor bladder emptying.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Kidney Diseases Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Male Urogenital Diseases Tomography Urogenital Diseases Urologic Diseases X-Ray Computed

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Assistance Publique Hôpitaux de Paris - CHU Henri Mondor - Créteil

Créteil, Île-de-France Region, 94000, France

Location contact

Thomas STEHLE, Dr

CONTACT

[email protected]

+33145178452

About this study

Objective: To assess whether GFR measurement using 4-phase CT urography is reliable in patients with GFR below 60 ml/min/1.73 m², as compared with iohexol clearance (reference method): - Unbiased (mean difference between CT-measured GFR and iohexol clearance not different from zero). - and accurate: at least 50% and 80% of GFR values measured by CT urography within 10% and 20% of biological clearance values for iohexol clearance.

Method: Single-center interventional study. After performing a 4-phase CT urography (or 3-phase CT scan, with the addition of a 4th phase for research purposes), performed for clinical indications as part of the patient's care, and using iohexol as a contrast agent, patients will undergo a biological measurement of iohexol clearance, based on serum and urine samples taken over 4 periods of 1 hour, between 3 and 7 hours after the CT scan. No iohexol will be reinjected to measure GFR. The CT scan images will be segmented by the investigator to determine the CT-measured GFR.

The inclusion criteria are: - Patients older than 18 years of age - Having given written consent to participate in the study. - Patient referred to the medical imaging department of the Henri Mondor University Hospital for a 3-phase or 4-phase abdominal CT scan. - With an estimated GFR according to CKD-EPIcreat2009 < 60 ml/min/1.73m² - Hospitalized or outpatient. - Affiliated with French national health insurance.

The exclusion criteria are: - Patients with hip implants, due to artifacts that make quantification of the contrast agent in the bladder unreliable. - Lack of health insurance - Patients under legal protection.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients older than 18 years of age
  • Having given written consent to participate in the study
  • Patient referred to the medical imaging department of the Henri Mondor University Hospital for a 3-phase or 4-phase abdominal CT scan
  • With an estimated GFR according to CKD-EPIcreat2009 < 60 ml/min/1.73m²
  • Hospitalized or outpatient
  • Affiliated with French national health insurance

Exclusion criteria

  • Patients with hip implants, due to artifacts that make quantification of the contrast agent in the bladder unreliable
  • Lack of health insurance
  • Patients under legal protection.

Treatment and study plan

Glomerular Filtration Rate measurement with iohexol clearance

Other

After performing a 4-phase CT urography (or 3-phase CT scan, with the addition of a 4th phase for research purposes), performed for clinical indications as part of the patient's care, and using iohexol as a contrast agent, patients will undergo a biological measurement of iohexol clearance, based on serum and urine samples taken over 4 periods of 1 hour, between 3 and 7 hours after the CT scan. No iohexol will be reinjected to measure GFR. The CT scan images will be segmented by the investigator to determine the CT-measured GFR.

Primary outcomes

  1. Assessment of the Reliability of GFR Measurement by 4-Phase CT Urography Compared to Iohexol Clearance

    Time frame: Day 1

    To assess whether GFR measurement using 4-phase CT urography is reliable in patients with GFR below 60 ml/min/1.73 m², as compared with iohexol clearance (reference method): - Unbiased (mean difference between CT-measured GFR and iohexol clearance not different from zero). - and accurate: at least 50% and 80% of GFR values measured by CT urography within 10% and 20% of biological clearance values for iohexol clearance.

Secondary outcomes

  1. Reliability Assessment of GFR Estimation Using Creatinine and/or Cystatin C Compared to Iohexol Clearance

    Time frame: Day 1

    This outcome measure assesses the reliability of glomerular filtration rate (GFR) estimated from serum creatinine and/or cystatin C levels by comparing it to the biological measurement of iohexol clearance.

  2. Reliability of Hybrid GFR (Mean of CT-Measured and Creatinine/Cystatin C Estimated GFR)

    Time frame: Day 1

    This outcome measure evaluates the reliability of the hybrid GFR, defined as the average of the GFR measured by 4-phase CT urography and the GFR estimated from serum creatinine and cystatin C. The reliability will be compared to that of CT-measured GFR alone and creatinine/cystatin C-based estimated GFR,

  3. Reliability of CT-Measured GFR Across Patient Subgroups Defined by Estimated GFR Ranges

    Time frame: Day 1

    This outcome measure assesses the reliability of GFR measured by 4-phase CT urography within different patient subgroups based on their estimated GFR values: between 45 and 60 ml/min/1.73m², between 30 and 44 ml/min/1.73m², and less than 30 ml/min/1.73m²

Study contacts

Contact information is provided by the study sponsor or research team.

Thomas STEHLE, Dr

CONTACT

[email protected]

+33145178452

Sponsors and collaborators

Lead sponsor

Assistance Publique - Hôpitaux de Paris

Other

Registry information

Official study title

Evaluation of the Performance of Glomerular Filtration Rate Measurement Using CT Urography in Patients With Chronic Kidney Disease

Acronym: DUSIR

Important dates

Study start
2025
Primary completion
2027
Study completion
2027
First posted
Jun 29, 2025
Registry last updated
Jun 29, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.